Significance of Drug Substance Physicochemical Properties in Regulatory Quality by Design

Preformulation in Solid Dosage Form Development

Volumn , Issue , 2008, Pages 571-583

  Lee, Sau Lawrence ^a   Raw, Andre S ^a   Yu, Lawrence ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953146976     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849360862-21     Document Type: Chapter

References (36)

1. Woodcock J. Ind Pharmacy 2005; 5:6-9.
2. ICH, Q9 Quality Risk Management, ICH, June 2006.
3. ICH, Q8 Pharmaceutical Development, ICH, May 2006.
4. Woodcock J. Am Pharm J Rev 2004; 7:6-9.
5. Higuchi T, Shih FM, Kimura T, Rytting JH. J Pharm Sci 1979; 68:1267-72.
6. Ando HY, Radebaugh GW. Preformulation. In: Gennaro AR, ed. Remington: The Science and Practice of Pharmacy. Maryland: Lippincott Williams & Wilkins, 2000:700-20.
7. Stavchansky R, McGinity J. Bioavailability and tablet technology. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets, Vol. 2. New York: Marcel Dekker, 1989:349-569.
8. Wolf B, Finke I, Schmitz W. Pharmazie 1996; 51:104-12.
9. Loftsson T, Hreinsdóttir D, Másson M. Inter J Pharm 2005; 302:18-28.
10. Curatolo W. Pharm Sci Technol Today 1998; 1:387-93.
11. Avdeef A. Absorption and Drug Development: Solubility, Permeability, and Charge State. New Jersey: Wiley, 2003.
12. Amidon GL, Lennernäs H, Shah VP, Crison JR. Pharm Res 1995; 12:413-9.
13. Corrigan OI. Adv Exp Med Biol 1997; 423:111-28.
14. Stewart PJ, Tucker IG. Aust J Hosp Pharm 1985; 185:11-6.
15. Waterman KC, Adami RC. Inter J Pharm 2005; 293:101-25.
16. Wirth DD, Baertschi SW, John RA, et al. J Pharm Sci 1998; 87:31-9.
17. European Pharmacopeia 5.0. 2005; 5:565.
18. Waterman KC, Adami, RC, Alsante KM, et al. Pharm Dev Tech 2002; 7:1113-46.
19. Orford PD, Parker R, Ring SG. Carbohydr Res 1990; 196:11-8.
20. Roos Y. Carbohydr Res 1993; 238:39-48.
21. Ahlneck C, Zografi G. Inter J Pharm 1990; 62:87-95.
22. Callahan JC, Cleary GW, Elefant M, Kaplan G, Kensler T, Nash RA. Drug Dev Ind Pharm 1982; 8:355-69.
23. Wadke DA, Serajuddin ATM, Jacobson H. Preformulation testing. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets, Vol. 1. New York: Marcel Dekker, 1989:1-71.
24. Weng H, Parrott EL. J Pharm Sci 1984; 73:1059-63.
25. Gregg SJ, Sing KSW. Adsorption, Surface Area, and Porosity. New York: Academic Press, 1967.
26. Yu L. Adv Drug Delivery Rev 2001; 48:27-42.
27. Grant DJW. Theory and origin of polymorphism. In: Brittain HG, ed. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker 1999; 1-34.
28. Aguiar AJ, Krc J, Kinkel AW, Symyn JC. J Pharm Sci 1967; 56:847-53.
29. Aguiar AJ, Zelmer JE. J Pharma Sci 1969; 58:983-7.
30. Yu LX, Amidon GL, Polli JE, et al. Pharm Res 2002; 19:921-5.
31. Eyjolfsson R. Pharmazie 57:347-8.
32. Chen X, Morris KR, Griesser UJ, Byrn SR, Stowell JG. J Am Chem Soc 2002; 124:15012-9.
33. De Villiers MM, van der Watt JG, Lotter AP. Int J Pharm 1992; 88:275-83.
34. Matsuda Y, Akazawa R, Teraoka R, Otsuka M. J Pharm Phamacol 1993; 46: 162-7.
35. Brittain HG, Grant DJW. Methods for the characterization of polymorphs and solvates. In: Brittain HG, ed. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker, 1999; 227-78.
36. Yu L, Reutzel SM. Pharm Sci Tech 1998; 1:118-27.